Liver Disease in Type 2 Diabetes: MASLD, Fibrosis & Silent Progression Risks

Type 2 Diabetes is a growing global health challenge, with the World Health Organization (WHO) estimating over 420 million cases worldwide, mostly Type 2. 

• In India, this rise is accompanied by increasing Metabolic dysfunction-associated steatotic liver disease, often undiagnosed until advanced stages.

UPSC Online Courses

Key Findings and Data

• High Co-Occurrence: Up to 70% of individuals with Type 2 Diabetes (T2D) are estimated to have a strong association between metabolic disorders and liver disease.
• Silent Progression: A significant proportion of patients remain asymptomatic, with nearly one-third showing underlying liver fibrosis without clinical signs.
• Global Evidence: A large multinational study published in The Lancet found that:
  • Around 4.6% of adults had significant liver stiffness, and
  • Nearly 1.6% had confirmed fibrosis, often undiagnosed.
• Elevated Risk in Diabetics: Patients with T2D face double the risk of developing advanced fibrosis compared to non-diabetic individuals.

About Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

• Definition and Nature: T2DM is a chronic metabolic disorder characterised by insulin resistance and relative insulin deficiency, leading to persistent hyperglycaemia, whereas MASLD refers to the accumulation of excess fat in the liver in the absence of significant alcohol intake, driven primarily by metabolic dysfunction.
• Common Pathophysiological Basis: Both conditions share a common underlying mechanism of insulin resistance, which disrupts normal glucose and lipid metabolism and results in hepatic fat accumulation (steatosis).
• Disease Spectrum and Progression: MASLD represents a continuum ranging from simple steatosis (fat accumulation) to metabolic dysfunction-associated steatohepatitis (MASH), which may further progress to liver fibrosis (scarring), cirrhosis, and hepatocellular carcinoma if left untreated.
• High Co-Occurrence and Epidemiological Link: A substantial proportion of individuals with T2DM, estimated to be up to 70%, also develop MASLD, making it one of the most common comorbid conditions associated with diabetes.
• Silent Nature and Clinical Risk: Both T2DM and MASLD often remain clinically silent in their early stages, but they significantly increase the risk of cardiovascular diseases, chronic liver disease, liver failure, and liver cancer in the long term.
• Bidirectional Relationship: MASLD further aggravates insulin resistance, thereby worsening glycaemic control in T2DM and creating a vicious cycle of metabolic dysfunction.
• Importance of Early Detection and Management: Early screening using liver function tests (LFTs), fibrosis scoring systems such as Fibrosis-4 (FIB-4), and imaging techniques like FibroScan is essential, while management relies on lifestyle modification, weight reduction, glycaemic control, lipid regulation, and appropriate pharmacological interventions to prevent disease progression.

Explore UPSC Foundation Courses

Explore UPSC Foundation Courses

Understanding the Disease Mechanism

• Insulin Resistance as the Core Driver: Insulin resistance, the hallmark of T2D, disrupts the metabolism of glucose, fats, and proteins.
  • This leads to fat accumulation in the liver (hepatic steatosis), which is the earliest stage of MASLD.
• Progression from Fat to Fibrosis: In some individuals, fat accumulation triggers inflammation (steatohepatitis).
  • Over time, this may progress to fibrosis, cirrhosis, and even liver cancer.
• Role of Metabolic and Genetic Factors: Conditions such as obesity, dyslipidaemia, and hypothyroidism accelerate liver damage.
  • Additional contributors include:
    • Lipotoxicity from free fatty acids,
    • Glycated proteins, and
    • Gut microbiota imbalance.
  • Genetic predisposition also plays a crucial role, explaining cases like “lean NASH”, where non-obese individuals develop fatty liver disease.

Why Liver Disease Often Goes Unnoticed

• Absence of Early Symptoms: Liver disease progresses silently because the liver has high functional reserve and lacks pain receptors.
• Late Clinical Manifestation: Symptoms such as fatigue, jaundice, abdominal swelling, and fluid accumulation appear only in advanced stages.
• Delayed Diagnosis: The disease is often detected incidentally through blood tests, ultrasound, or FibroScan, by which time significant damage may have occurred.

Best Online Coaching for UPSC

Importance of Early Screening

• Detection of Hidden Fibrosis: Studies suggest that up to 35% of T2D patients may have fibrosis without symptoms, making proactive screening essential.
• Use of Non-Invasive Tools: Screening can be effectively done using:
  • Liver Function Tests (LFTs),
  • Fibrosis scoring systems (e.g., FIB-4), and
  • Imaging techniques such as FibroScan and CAP score.
• Prevention of Disease Progression: Early detection allows timely interventions, including:
  • Weight management,
  • Improved glycaemic and lipid control, and
  • Pharmacological treatment using drugs like pioglitazone and GLP-1 receptor agonists such as Semaglutide.

Public Health Significance

• Rising Dual Burden: The coexistence of diabetes and liver disease represents a major public health challenge, particularly in countries like India.
• Risk of Severe Outcomes: Advanced fibrosis can lead to cirrhosis, liver failure, and hepatocellular carcinoma, increasing morbidity and mortality.
• Need for Integrated Care: Incorporating liver screening into routine diabetes management can significantly reduce long-term complications.

Explore UPSC Prarambh Course

Explore UPSC Prarambh Course

Challenges and Concerns

• Lack of Awareness: Both patients and primary healthcare providers often underestimate the risk of liver disease in diabetes.
• Limited Screening Integration: Routine liver screening is not yet standard practice in diabetes care protocols.
• Diagnostic Gaps: Access to advanced diagnostic tools such as FibroScan remains limited in many regions.
• Complex Risk Profile: The presence of multiple contributing factors, including alcohol use, viral hepatitis, and genetic disorders, complicates diagnosis and management.

Way Forward

• Integrating Screening into Diabetes Care: Routine liver assessment should become a standard component of diabetes management protocols.
• Strengthening Primary Healthcare: Capacity building at the primary care level is essential for early identification and referral.
• Promoting Lifestyle Interventions: Public health strategies should emphasise diet, physical activity, and weight management.
• Improving Awareness and Research: Greater awareness campaigns and research into lean NASH and metabolic liver disease are needed.

Click to Explore UPSC Offline Coaching

Conclusion

Liver disease in Type 2 diabetes represents a silent but serious health threat, often going undetected until irreversible stages. Early screening and integrated care approaches can play a transformative role in reducing disease burden, preventing complications, and improving patient outcomes, making it a critical priority in public health policy.

Check Out UPSC CSE Books

Visit PW Store

DOWNLOAD PDF